Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms
of patients with chronic schizophrenia. In addition, several drugs with anti-inflammatory
properties have been tested in clinical trials for the treatment of schizophrenia too.
Whether combined treatment of an NMDA-enhancing agent and a drug with anti-inflammatory
property can be better than an NMDA-enhancing agent alone deserves study.